Sino Biopharm's Profit Jumps in H1

MT Newswires Live
08/18

Sino Biopharmaceutical (HKG:1177) recorded a rise in attributable profit in the first half of 2025 to 3.39 billion yuan from 3.02 billion yuan in the year-ago period, a Monday Hong Kong bourse filing said.

Earnings per share were 0.188 yuan in the half year, up from 0.1639 yuan in the corresponding period of the last fiscal year.

The biopharmaceutical company's revenue from continuing operations rose 11% to 17.6 billion yuan in the interim period from 15.9 billion yuan a year prior.

The firm declared an interim dividend of HK$0.05 per share for the period, payable Sept. 23 to shareholders of record on Sept. 3.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10